- Report
- June 2023
- 112 Pages
Global
From €3992EUR$4,500USD£3,485GBP
- Report
- October 2024
- 200 Pages
Global
From €3327EUR$3,750USD£2,904GBP
- Report
- March 2024
- 200 Pages
Global
From €3682EUR$4,150USD£3,214GBP
- Report
- August 2023
- 117 Pages
Global
From €3992EUR$4,500USD£3,485GBP
- Report
- August 2023
- 120 Pages
Global
From €3992EUR$4,500USD£3,485GBP
- Report
- May 2023
- 120 Pages
Global
From €3992EUR$4,500USD£3,485GBP
- Report
- August 2024
- 150 Pages
Global
From €3416EUR$3,850USD£2,981GBP
€4303EUR$4,850USD£3,756GBP
- Report
- November 2023
- 76 Pages
Global
From €3992EUR$4,500USD£3,485GBP
- Report
- November 2023
- 125 Pages
Global
From €3500EUR$4,226USD£3,162GBP
- Report
- November 2023
- 92 Pages
Global
From €3500EUR$4,226USD£3,162GBP
- Report
- November 2021
- 1032 Pages
Global
From €4436EUR$5,000USD£3,872GBP

Biomarker validation is the process of determining the accuracy and reliability of a biomarker for use in medical research and diagnostics. It involves the evaluation of the biomarker's ability to accurately measure a biological process or disease state, as well as its ability to predict the outcome of a medical intervention. The validation process typically includes laboratory testing, clinical trials, and statistical analysis.
The biomarker validation market is a rapidly growing sector of the biotechnology industry, driven by the increasing demand for personalized medicine and the need for more accurate and reliable biomarkers. Companies in this market are focused on developing and validating biomarkers for a variety of diseases and conditions, including cancer, cardiovascular disease, and neurological disorders.
Some of the major companies in the biomarker validation market include Illumina, Qiagen, Thermo Fisher Scientific, Roche, and Agilent Technologies. Show Less Read more